- Home
- EVOK vs HEPA Comparison
EVOK vs HEPA Comparison
Compare EVOK & HEPA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EVOK
- HEPA
- Stock Information
- Founded
- EVOK 2007
- HEPA 2013
- Country
- EVOK United States
- HEPA United States
- Employees
- EVOK N/A
- HEPA N/A
- Industry
- EVOK Biotechnology: Pharmaceutical Preparations
- HEPA Biotechnology: Pharmaceutical Preparations
- Sector
- EVOK Health Care
- HEPA Health Care
- Exchange
- EVOK Nasdaq
- HEPA Nasdaq
- Market Cap
- EVOK 4.3M
- HEPA 4.7M
- IPO Year
- EVOK 2013
- HEPA N/A
- Fundamental
- Price
- EVOK $4.41
- HEPA $0.66
- Analyst Decision
- EVOK
- HEPA Hold
- Analyst Count
- EVOK 0
- HEPA 1
- Target Price
- EVOK N/A
- HEPA N/A
- AVG Volume (30 Days)
- EVOK 1.2M
- HEPA 29.0K
- Earning Date
- EVOK 11-07-2024
- HEPA 11-14-2024
- Dividend Yield
- EVOK N/A
- HEPA N/A
- EPS Growth
- EVOK N/A
- HEPA N/A
- EPS
- EVOK N/A
- HEPA N/A
- Revenue
- EVOK $8,617,036.00
- HEPA N/A
- Revenue This Year
- EVOK $124.10
- HEPA N/A
- Revenue Next Year
- EVOK $75.70
- HEPA N/A
- P/E Ratio
- EVOK N/A
- HEPA N/A
- Revenue Growth
- EVOK 100.35
- HEPA N/A
- 52 Week Low
- EVOK $3.54
- HEPA $0.55
- 52 Week High
- EVOK $17.40
- HEPA $4.47
- Technical
- Relative Strength Index (RSI)
- EVOK 40.54
- HEPA 48.87
- Support Level
- EVOK $4.28
- HEPA $0.59
- Resistance Level
- EVOK $4.79
- HEPA $0.74
- Average True Range (ATR)
- EVOK 0.45
- HEPA 0.06
- MACD
- EVOK -0.13
- HEPA 0.00
- Stochastic Oscillator
- EVOK 22.82
- HEPA 48.07
About EVOK Evoke Pharma Inc.
Evoke Pharma Inc is a specialty pharmaceutical company focused on the development and commercialization of drugs to treat gastrointestinal, or GI, disorders, and diseases. The company's product Gimoti is an investigational metoclopramide nasal spray for the relief of symptoms associated with acute and recurrent diabetic gastroparesis in women. Gimoti is a novel nasal spray formulation of metoclopramide designed to provide systemic delivery of the molecule through the nasal mucosa.
About HEPA Hepion Pharmaceuticals Inc.
Hepion Pharmaceuticals Inc is a biopharmaceutical company that focuses primarily on the development of drug therapy for the treatment of chronic liver diseases. This therapeutic approach targets fibrosis and hepatocellular carcinoma associated with non-alcoholic steatohepatitis, viral hepatitis, and other liver diseases. Its cyclophilin inhibitor, Rencofilstat, is being developed to offer benefits to address these multiple complex pathologies. Rencofilstat is a pan-cyclophilin inhibitor that targets multiple pathologic pathways involved in the progression of liver disease.